Global Tuberculosis Therapeutics Market to Reach $1.1 Billion by 2030
The global market for Tuberculosis Therapeutics estimated at US$863 Million in the year 2022, is projected to reach a revised size of US$1.1 Billion by 2030, growing at a CAGR of 2.7% over the analysis period 2022-2030. Active TB, one of the segments analyzed in the report, is projected to record 2.9% CAGR and reach US$654.3 Million by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Latent TB segment is readjusted to a revised 2.4% CAGR for the next 8-year period.The U.S. Market is Estimated at $235.1 Million, While China is Forecast to Grow at 4.7% CAGR
The Tuberculosis Therapeutics market in the U.S. is estimated at US$235.1 Million in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$208.6 Million by the year 2030 trailing a CAGR of 4.7% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 1.5% and 2.4% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 1.8% CAGR.Select Competitors (Total 37 Featured) -
- AstraZeneca PLC
- Eli Lilly and Company
- GlaxoSmithKline PLC
- Johnson & Johnson
- Lupin Ltd.
- Merck & Co., Inc.
- Otsuka Pharmaceutical Co., Ltd.
- Panacea Biotec Ltd.
- Pfizer, Inc.
What's New?
- Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
- Global competitiveness and key competitor percentage market shares
- Market presence across multiple geographies - Strong/Active/Niche/Trivial
- Online interactive peer-to-peer collaborative bespoke updates
- Access to digital archives and Research Platform
- Complimentary updates for one year
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERS3. MARKET TRENDS & DRIVERSIII. MARKET ANALYSISSOUTH KOREAREST OF ASIA-PACIFICARGENTINABRAZILMEXICOREST OF LATIN AMERICAIRANISRAELSAUDI ARABIAUNITED ARAB EMIRATESREST OF MIDDLE EASTIV. COMPETITION
1. MARKET OVERVIEW
- Influencer Market Insights
- World Market Trajectories
- Tuberculosis Therapeutics - Global Key Competitors Percentage Market Share in 2022 (E)
- Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
- Impact of Covid-19 and a Looming Global Recession
4. GLOBAL MARKET PERSPECTIVE
- Table 1: World Recent Past, Current & Future Analysis for Tuberculosis Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
- Table 2: World Historic Review for Tuberculosis Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2021 and % CAGR
- Table 3: World 18-Year Perspective for Tuberculosis Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2012, 2023 & 2030
- Table 4: World Recent Past, Current & Future Analysis for Active TB by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
- Table 5: World Historic Review for Active TB by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2021 and % CAGR
- Table 6: World 18-Year Perspective for Active TB by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2023 & 2030
- Table 7: World Recent Past, Current & Future Analysis for Latent TB by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
- Table 8: World Historic Review for Latent TB by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2021 and % CAGR
- Table 9: World 18-Year Perspective for Latent TB by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2023 & 2030
- Table 10: World Recent Past, Current & Future Analysis for First-Line by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
- Table 11: World Historic Review for First-Line by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2021 and % CAGR
- Table 12: World 18-Year Perspective for First-Line by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2023 & 2030
- Table 13: World Recent Past, Current & Future Analysis for Second-Line by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
- Table 14: World Historic Review for Second-Line by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2021 and % CAGR
- Table 15: World 18-Year Perspective for Second-Line by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2023 & 2030
- Table 16: World Tuberculosis Therapeutics Market Analysis of Annual Sales in US$ Thousand for Years 2012 through 2030
UNITED STATES
- Tuberculosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
- Table 17: USA Recent Past, Current & Future Analysis for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 18: USA Historic Review for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2021 and % CAGR
- Table 19: USA 18-Year Perspective for Tuberculosis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Active TB and Latent TB for the Years 2012, 2023 & 2030
- Table 20: USA Recent Past, Current & Future Analysis for Tuberculosis Therapeutics by Therapy - First-Line and Second-Line - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 21: USA Historic Review for Tuberculosis Therapeutics by Therapy - First-Line and Second-Line Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2021 and % CAGR
- Table 22: USA 18-Year Perspective for Tuberculosis Therapeutics by Therapy - Percentage Breakdown of Value Sales for First-Line and Second-Line for the Years 2012, 2023 & 2030
CANADA
- Table 23: Canada Recent Past, Current & Future Analysis for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 24: Canada Historic Review for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2021 and % CAGR
- Table 25: Canada 18-Year Perspective for Tuberculosis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Active TB and Latent TB for the Years 2012, 2023 & 2030
- Table 26: Canada Recent Past, Current & Future Analysis for Tuberculosis Therapeutics by Therapy - First-Line and Second-Line - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 27: Canada Historic Review for Tuberculosis Therapeutics by Therapy - First-Line and Second-Line Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2021 and % CAGR
- Table 28: Canada 18-Year Perspective for Tuberculosis Therapeutics by Therapy - Percentage Breakdown of Value Sales for First-Line and Second-Line for the Years 2012, 2023 & 2030
JAPAN
- Tuberculosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
- Table 29: Japan Recent Past, Current & Future Analysis for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 30: Japan Historic Review for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2021 and % CAGR
- Table 31: Japan 18-Year Perspective for Tuberculosis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Active TB and Latent TB for the Years 2012, 2023 & 2030
- Table 32: Japan Recent Past, Current & Future Analysis for Tuberculosis Therapeutics by Therapy - First-Line and Second-Line - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 33: Japan Historic Review for Tuberculosis Therapeutics by Therapy - First-Line and Second-Line Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2021 and % CAGR
- Table 34: Japan 18-Year Perspective for Tuberculosis Therapeutics by Therapy - Percentage Breakdown of Value Sales for First-Line and Second-Line for the Years 2012, 2023 & 2030
CHINA
- Tuberculosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
- Table 35: China Recent Past, Current & Future Analysis for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 36: China Historic Review for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2021 and % CAGR
- Table 37: China 18-Year Perspective for Tuberculosis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Active TB and Latent TB for the Years 2012, 2023 & 2030
- Table 38: China Recent Past, Current & Future Analysis for Tuberculosis Therapeutics by Therapy - First-Line and Second-Line - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 39: China Historic Review for Tuberculosis Therapeutics by Therapy - First-Line and Second-Line Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2021 and % CAGR
- Table 40: China 18-Year Perspective for Tuberculosis Therapeutics by Therapy - Percentage Breakdown of Value Sales for First-Line and Second-Line for the Years 2012, 2023 & 2030
EUROPE
- Tuberculosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
- Table 41: Europe Recent Past, Current & Future Analysis for Tuberculosis Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
- Table 42: Europe Historic Review for Tuberculosis Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2021 and % CAGR
- Table 43: Europe 18-Year Perspective for Tuberculosis Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2012, 2023 & 2030
- Table 44: Europe Recent Past, Current & Future Analysis for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 45: Europe Historic Review for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2021 and % CAGR
- Table 46: Europe 18-Year Perspective for Tuberculosis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Active TB and Latent TB for the Years 2012, 2023 & 2030
- Table 47: Europe Recent Past, Current & Future Analysis for Tuberculosis Therapeutics by Therapy - First-Line and Second-Line - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 48: Europe Historic Review for Tuberculosis Therapeutics by Therapy - First-Line and Second-Line Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2021 and % CAGR
- Table 49: Europe 18-Year Perspective for Tuberculosis Therapeutics by Therapy - Percentage Breakdown of Value Sales for First-Line and Second-Line for the Years 2012, 2023 & 2030
FRANCE
- Tuberculosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
- Table 50: France Recent Past, Current & Future Analysis for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 51: France Historic Review for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2021 and % CAGR
- Table 52: France 18-Year Perspective for Tuberculosis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Active TB and Latent TB for the Years 2012, 2023 & 2030
- Table 53: France Recent Past, Current & Future Analysis for Tuberculosis Therapeutics by Therapy - First-Line and Second-Line - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 54: France Historic Review for Tuberculosis Therapeutics by Therapy - First-Line and Second-Line Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2021 and % CAGR
- Table 55: France 18-Year Perspective for Tuberculosis Therapeutics by Therapy - Percentage Breakdown of Value Sales for First-Line and Second-Line for the Years 2012, 2023 & 2030
GERMANY
- Tuberculosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
- Table 56: Germany Recent Past, Current & Future Analysis for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 57: Germany Historic Review for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2021 and % CAGR
- Table 58: Germany 18-Year Perspective for Tuberculosis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Active TB and Latent TB for the Years 2012, 2023 & 2030
- Table 59: Germany Recent Past, Current & Future Analysis for Tuberculosis Therapeutics by Therapy - First-Line and Second-Line - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 60: Germany Historic Review for Tuberculosis Therapeutics by Therapy - First-Line and Second-Line Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2021 and % CAGR
- Table 61: Germany 18-Year Perspective for Tuberculosis Therapeutics by Therapy - Percentage Breakdown of Value Sales for First-Line and Second-Line for the Years 2012, 2023 & 2030
ITALY
- Table 62: Italy Recent Past, Current & Future Analysis for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 63: Italy Historic Review for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2021 and % CAGR
- Table 64: Italy 18-Year Perspective for Tuberculosis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Active TB and Latent TB for the Years 2012, 2023 & 2030
- Table 65: Italy Recent Past, Current & Future Analysis for Tuberculosis Therapeutics by Therapy - First-Line and Second-Line - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 66: Italy Historic Review for Tuberculosis Therapeutics by Therapy - First-Line and Second-Line Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2021 and % CAGR
- Table 67: Italy 18-Year Perspective for Tuberculosis Therapeutics by Therapy - Percentage Breakdown of Value Sales for First-Line and Second-Line for the Years 2012, 2023 & 2030
UNITED KINGDOM
- Tuberculosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
- Table 68: UK Recent Past, Current & Future Analysis for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 69: UK Historic Review for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2021 and % CAGR
- Table 70: UK 18-Year Perspective for Tuberculosis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Active TB and Latent TB for the Years 2012, 2023 & 2030
- Table 71: UK Recent Past, Current & Future Analysis for Tuberculosis Therapeutics by Therapy - First-Line and Second-Line - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 72: UK Historic Review for Tuberculosis Therapeutics by Therapy - First-Line and Second-Line Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2021 and % CAGR
- Table 73: UK 18-Year Perspective for Tuberculosis Therapeutics by Therapy - Percentage Breakdown of Value Sales for First-Line and Second-Line for the Years 2012, 2023 & 2030
SPAIN
- Table 74: Spain Recent Past, Current & Future Analysis for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 75: Spain Historic Review for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2021 and % CAGR
- Table 76: Spain 18-Year Perspective for Tuberculosis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Active TB and Latent TB for the Years 2012, 2023 & 2030
- Table 77: Spain Recent Past, Current & Future Analysis for Tuberculosis Therapeutics by Therapy - First-Line and Second-Line - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 78: Spain Historic Review for Tuberculosis Therapeutics by Therapy - First-Line and Second-Line Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2021 and % CAGR
- Table 79: Spain 18-Year Perspective for Tuberculosis Therapeutics by Therapy - Percentage Breakdown of Value Sales for First-Line and Second-Line for the Years 2012, 2023 & 2030
RUSSIA
- Table 80: Russia Recent Past, Current & Future Analysis for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 81: Russia Historic Review for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2021 and % CAGR
- Table 82: Russia 18-Year Perspective for Tuberculosis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Active TB and Latent TB for the Years 2012, 2023 & 2030
- Table 83: Russia Recent Past, Current & Future Analysis for Tuberculosis Therapeutics by Therapy - First-Line and Second-Line - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 84: Russia Historic Review for Tuberculosis Therapeutics by Therapy - First-Line and Second-Line Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2021 and % CAGR
- Table 85: Russia 18-Year Perspective for Tuberculosis Therapeutics by Therapy - Percentage Breakdown of Value Sales for First-Line and Second-Line for the Years 2012, 2023 & 2030
REST OF EUROPE
- Table 86: Rest of Europe Recent Past, Current & Future Analysis for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 87: Rest of Europe Historic Review for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2021 and % CAGR
- Table 88: Rest of Europe 18-Year Perspective for Tuberculosis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Active TB and Latent TB for the Years 2012, 2023 & 2030
- Table 89: Rest of Europe Recent Past, Current & Future Analysis for Tuberculosis Therapeutics by Therapy - First-Line and Second-Line - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 90: Rest of Europe Historic Review for Tuberculosis Therapeutics by Therapy - First-Line and Second-Line Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2021 and % CAGR
- Table 91: Rest of Europe 18-Year Perspective for Tuberculosis Therapeutics by Therapy - Percentage Breakdown of Value Sales for First-Line and Second-Line for the Years 2012, 2023 & 2030
ASIA-PACIFIC
- Tuberculosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
- Table 92: Asia-Pacific Recent Past, Current & Future Analysis for Tuberculosis Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
- Table 93: Asia-Pacific Historic Review for Tuberculosis Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2021 and % CAGR
- Table 94: Asia-Pacific 18-Year Perspective for Tuberculosis Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2012, 2023 & 2030
- Table 95: Asia-Pacific Recent Past, Current & Future Analysis for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 96: Asia-Pacific Historic Review for Tuberculosis Therapeutics by Disease Type - Active TB and Latent TB Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2021 and % CAGR
- Table 97: Asia-Pacific 18-Year Perspective for Tuberculosis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Active TB and Latent TB for the Years 2012, 2023 & 2030
- Table 98: Asia-Pacific Recent Past, Current & Future Analysis for Tuberculosis Therapeutics by Therapy - First-Line and Second-Line - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 99: Asia-Pacific Historic Review for Tuberculosis Therapeutics by Therapy - First-Line and Second-Line Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2021 and % CAGR
- Table 100: Asia-Pacific 18-Year Perspective for Tuberculosis Therapeutics by Therapy - Percentage Breakdown of Value Sales for First-Line and Second-Line for the Years 2012, 2023 & 2030
AUSTRALIA
- Tuberculosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2023 (E)
INDIA
- Tuberculosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2023 (E)
LATIN AMERICA
- Tuberculosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2023 (E)
MIDDLE EAST
- Tuberculosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2023 (E)
AFRICA
- Tuberculosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2023 (E)
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AstraZeneca PLC
- Eli Lilly and Company
- GlaxoSmithKline PLC
- Johnson & Johnson
- Lupin Ltd.
- Merck & Co., Inc.
- Otsuka Pharmaceutical Co., Ltd.
- Panacea Biotec Ltd.
- Pfizer, Inc.
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 283 |
Published | April 2024 |
Forecast Period | 2022 - 2030 |
Estimated Market Value ( USD | $ 863 Million |
Forecasted Market Value ( USD | $ 1100 Million |
Compound Annual Growth Rate | 3.1% |
Regions Covered | Global |